ORBIMED ADVISORS LLC
CIK 1055951 · last filed 2026-08-12
ORBIMED ADVISORS LLC is a corporate insider who has filed 232 SEC Form 4 insider transactions across 77 companies since 2007. The most recent filing, for BLSM, was dated Aug 12, 2026. Across all open-market trades the lifetime net is −$1.43B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.55B across reported positions. The firm reports its address in New York, NY. 207 SEC filings were submitted jointly with SAMUEL D ISALY.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.55B
Companies
77
Total Filings
232
Lifetime Open-Market Net
-$1.43B
Filer Profile
Reported Address
601 LEXINGTON AVENUE54TH FLOOR
NEW YORK, NY 10022
Phone
(212) 739-6400
State of Incorporation
DE
Related Filers
SAMUEL D ISALY — 207 joint filings, latest 2018-01-19
OrbiMed Capital GP VI LLC — 132 joint filings, latest 2026-04-23
OrbiMed Genesis GP LLC — 103 joint filings, latest 2026-08-11
OrbiMed Capital GP VII LLC — 91 joint filings, latest 2026-06-24
OrbiMed Capital GP V LLC — 82 joint filings, latest 2026-04-09
OrbiMed Capital GP IV LLC — 78 joint filings, latest 2024-07-02
OrbiMed Capital GP III LLC — 70 joint filings, latest 2018-08-21
ORBIMED CAPITAL LLC — 63 joint filings, latest 2026-04-23
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) Delisted | Director | 2,714,279 | — | — | $20.00M | 1 | 2026-08-12 |
| Braveheart Bio, Inc. (BRVE) Delisted | Director | 11,901,826 | — | — | $104.76M | 1 | 2026-08-11 |
| SCTX | Director | 348,825 | — | — | $30.00M | 1 | 2026-07-29 |
| SION | Director | 2,469,959 | $7.85 | $19.39M | -$78.99M | 7 | 2026-07-09 |
| ELVN | 10%+ Owner | 220,882 | $54.32 | $12.00M | -$117.04M | 1 | 2026-06-24 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 7,388,902 | $14.59 | $107.80M | $11.99M | 4 | 2026-06-17 |
| PASG | 10%+ Owner | 385,918 | $5.00 | $1.93M | $5.69M | 4 | 2024-12-06 |
| MBX | Director | 653,787 | $59.02 | $38.59M | $36.00M | 1 | 2024-09-17 |
| scPharmaceuticals Inc. (SCPH) Delisted | 10%+ Owner | 252,858 | $5.67 | $1.43M | $42.00M | 2 | 2024-08-15 |
| KROS | Director | 119,522 | $11.08 | $1.32M | -$33.01M | 1 | 2024-08-15 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | 755,635 | $52.95 | $40.01M | -$2.81M | 1 | 2024-07-17 |
| IRON | Director | 608,611 | $70.06 | $42.64M | -$76.34M | 3 | 2024-06-20 |
| NPCE | 10%+ Owner | 3,411,009 | $14.04 | $47.89M | -$17.22M | 5 | 2024-05-03 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 2,416,181 | $64.97 | $156.98M | $11.40M | 3 | 2024-01-16 |
| ImageneBio, Inc. (IKNA) Delisted | Director | 13,107 | $17.16 | $224.9K | $40.65M | 3 | 2023-09-14 |
| Damora Therapeutics, Inc. (GLTO) Delisted | 10%+ Owner | 84,236 | $28.69 | $2.42M | -$3.71M | 2 | 2023-08-02 |
| Turnstone Biologics Corp. (TSBX) Delisted | Director | 2,682,599 | $0.35 | $952.3K | $10.00M | 1 | 2023-07-24 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | Director | 17,063,000 | $4.06 | $69.28M | $4.39M | 1 | 2023-07-19 |
| TELA | 10%+ Owner | 2,891,542 | $0.97 | $2.80M | -$3.58M | 1 | 2023-04-21 |
| Verona Pharma plc (VRNA) Delisted | Director | 35,294,568 | $106.91 | $3.77B | -$272.00M | 1 | 2022-12-27 |
| Third Harmonic Bio, Inc. (THRD) Delisted | Director | 5,479,071 | $5.38 | $29.48M | $10.20M | 1 | 2022-09-21 |
| XTNT | Director | 215,415 | $0.35 | $74.5K | $6.81M | 5 | 2022-08-17 |
| EWTX | Director | 13,497,456 | $44.40 | $599.29M | $2.98M | 1 | 2022-05-20 |
| ARQT | 10%+ Owner | 3,937,764 | $23.89 | $94.05M | -$54.49M | 1 | 2022-04-08 |
| JANX | Director | 231,098 | $17.10 | $3.95M | -$2.46M | 1 | 2021-12-30 |
| Tricida, Inc. (TCDA) Delisted | Director | 27,584 | $0.11 | $3.0K | -$106.00M | 3 | 2021-11-17 |
| CMPX | Director | 3,571,428 | $2.00 | $7.14M | $56.25M | 1 | 2021-11-08 |
| CRVS | Director | 6,943,654 | $12.91 | $89.64M | $23.04M | 8 | 2021-09-22 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 96,216 | $2.65 | $255.0K | -$2.69M | 2 | 2021-09-08 |
| SpringWorks Therapeutics, Inc. (SWTX) Delisted | 10%+ Owner | 6,185,936 | $46.99 | $290.68M | -$8.20M | 1 | 2021-06-09 |
| SYNLOGIC, INC. (SYBX) Delisted | Director | 246,444 | $0.69 | $170.0K | $0 | 1 | 2021-04-22 |
| ORIC | Director | 2,395,334 | $12.04 | $28.84M | -$20.06M | 2 | 2021-03-26 |
| Decibel Therapeutics, Inc. (DBTX) Delisted | Director | 218,568 | $4.91 | $1.07M | $120.00M | 1 | 2021-02-19 |
| ACET | Director | 56,430 | $9.52 | $537.2K | $0 | 1 | 2021-02-18 |
| CTI BIOPHARMA CORP (CTIC) Delisted | 10%+ Owner | 7,520,600 | $9.09 | $68.36M | -$14.00M | 1 | 2021-01-11 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | Director | 1,427 | $33.00 | $47.1K | $5.90M | 2 | 2020-12-10 |
| PRLD | Director | 917,412 | $4.59 | $4.21M | $70.50M | 2 | 2020-09-30 |
| CalciMedica, Inc. (GRAY) Delisted | 10%+ Owner | 297,382 | $5.50 | $1.64M | $18.00M | 1 | 2020-09-29 |
| 89bio, Inc. (ETNB) Delisted | Director | 1,864,721 | $14.84 | $27.67M | -$30.80M | 1 | 2020-09-23 |
| INSP | Director | 2,175,264 | $73.00 | $158.79M | -$145.13M | 4 | 2020-08-19 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | 2,224,770 | $21.55 | $47.94M | $45.80M | 1 | 2020-07-02 |
| Prevail Therapeutics Inc. (PRVL) Delisted | Director | 13,822,463 | — | — | $30.00M | 1 | 2019-06-26 |
| NXTC | Director | 37,156 | $7.00 | $260.1K | $10.50M | 1 | 2019-05-13 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 1,120,730 | $76.01 | $85.19M | $12.96M | 1 | 2019-04-24 |
| THOR | Director | 1,363,636 | $26.17 | $35.69M | $30.00M | 1 | 2018-12-13 |
| SIBN | Director | 785,368 | $18.38 | $14.44M | $6.00M | 1 | 2018-10-19 |
| GH | 10%+ Owner | 1,525,492 | $157.38 | $240.08M | $0 | 1 | 2018-10-11 |
| ViewRay, Inc. (VRAY) Delisted | 10%+ Owner | 74,555 | $0.03 | $1.9K | -$59.33M | 7 | 2018-08-21 |
| ASND | Director | 4,901,310 | $263.51 | $1.29B | -$29.24M | 3 | 2018-06-06 |
| RYTM | 10%+ Owner | 2,769,659 | $104.71 | $290.01M | -$8.13M | 1 | 2018-05-21 |
| BOLD | Director | 3,616,700 | $2.83 | $10.24M | -$40.86M | 3 | 2018-03-12 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 10%+ Owner | 617 | $13.60 | $8.4K | -$141.8K | 1 | 2018-02-15 |
| KALA | 10%+ Owner | 1,346 | $0.57 | $770 | $18.52M | 2 | 2018-02-02 |
| ARMO BioSciences, Inc. (ARMO) Delisted | Director | 409,547 | — | — | $0 | 1 | 2018-01-30 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 941,000 | — | — | -$98.10M | 2 | 2017-12-12 |
| Roka BioScience, Inc. (ROKA) Delisted | Director | 6,379 | — | — | -$719.9K | 3 | 2017-09-28 |
| GKOS | Director | 1,249,793 | $167.25 | $209.03M | -$114.29M | 3 | 2017-09-05 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | 10%+ Owner | 58,781 | $12.01 | $706.0K | $1.69M | 1 | 2017-02-21 |
| Relypsa Inc (RLYP) Delisted | 10%+ Owner | 3,356,400 | — | — | -$388.16M | 1 | 2016-07-26 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 12,193 | $0.88 | $10.7K | $23.10M | 1 | 2016-06-29 |
| OTONOMY, INC. (OTIC) Delisted | Director | 1,850,684 | $0.08 | $142.5K | $2.43M | 2 | 2015-11-30 |
| Dimension Therapeutics, Inc. (DMTX) Delisted | Director | 3,250,085 | — | — | $7.80M | 1 | 2015-10-29 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 1,271,901 | $19.00 | $24.17M | -$438.39M | 7 | 2015-03-30 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 1,176,717 | $58.70 | $69.07M | -$413.2K | 2 | 2014-07-01 |
| ACCELERON PHARMA INC (XLRN) Delisted | 498,739 | $178.75 | $89.15M | $0 | 1 | 2013-09-26 | |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | 10%+ Owner | 1,464,322 | $0.54 | $790.1K | $700.5K | 1 | 2013-05-24 |
| SUPN | 10%+ Owner | 858,100 | $41.64 | $35.73M | -$6.84M | 1 | 2013-02-14 |
| AMRN | Director | 59,430 | $13.80 | $820.1K | -$35.03M | 4 | 2012-06-19 |
| PCRX | 10%+ Owner | 2,588,200 | $25.36 | $65.64M | -$7.77M | 2 | 2012-02-03 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | 45,547 | — | — | -$8.54M | 5 | 2011-11-18 |
| ATHERSYS, INC / NEW (ATHX) Delisted | Director | 64,323 | $0.01 | $868 | -$1.16M | 4 | 2011-04-29 |
| NxStage Medical, Inc. (NXTM) Delisted | Director | 2,690,476 | — | — | -$14.97M | 9 | 2010-12-13 |
| GNOM | 10%+ Owner | 9,803 | $62.22 | $609.9K | $5.43M | 1 | 2010-11-16 |
| ARYx Therapeutics, Inc. (ARYX) Delisted | Director | 1,340,139 | — | — | -$10.00M | 3 | 2009-05-26 |
| ALBIREO PHARMA, INC. (BIOD) Delisted | Director | 60,430 | — | — | -$4.46M | 2 | 2008-02-14 |
| CRYOCOR INC (CRYO) Delisted | 10%+ Owner | 389,432 | — | — | $0 | 1 | 2007-06-19 |
| PODD | Director | 1,568,841 | $131.96 | $207.02M | $0 | 1 | 2007-05-18 |
Recent Filings
232 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-12 | BlossomHill Therapeutics, Inc. (BLSM) Delisted | Mixed | +5,428,558 | $20.00M | EDGAR |
| 2026-08-11 | Braveheart Bio, Inc. (BRVE) Delisted | Mixed | +33,217,260 | $104.76M | EDGAR |
| 2026-07-29 | SCTX | Mixed | +2,697,650 | $30.00M | EDGAR |
| 2026-07-09 | SION | Sell (S) | −171,836 | -$7.71M | EDGAR |
| 2026-07-02 | SION | Sell (S) | −231,688 | -$10.54M | EDGAR |
| 2026-06-24 | ELVN | Sell (S) | −2,580,369 | -$117.04M | EDGAR |
| 2026-06-22 | ELVN | Notice (144) | −24,846 | -$1.14M | EDGAR |
| 2026-06-22 | ELVN | Notice (144) | −787,024 | -$36.17M | EDGAR |
| 2026-06-17 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −844,224 | -$38.01M | EDGAR |
| 2026-06-15 | ELVN | Notice (144) | −272,322 | -$11.54M | EDGAR |
Showing 1–10 of 232
Page 1 of 24
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.